초록 열기/닫기 버튼


Purpose: This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. Materials and Methods: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1,000 mg/m2 intravenous (IV) 24 hour infusion (Day 1∼3), leucovorin 20 mg/m2 (Day 1∼3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks. Results: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4∼ 24), the median time to response was 8 weeks (range: 8∼20) the median time to progression was 30.0 weeks (95% CI: 16.3∼43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7∼70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity. Conclusion: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients. (Cancer Res Treat. 2003;35:123-129)


Purpose: This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. Materials and Methods: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1,000 mg/m2 intravenous (IV) 24 hour infusion (Day 1∼3), leucovorin 20 mg/m2 (Day 1∼3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks. Results: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4∼ 24), the median time to response was 8 weeks (range: 8∼20) the median time to progression was 30.0 weeks (95% CI: 16.3∼43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7∼70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity. Conclusion: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients. (Cancer Res Treat. 2003;35:123-129)


키워드열기/닫기 버튼

이 키워드로 연구동향 분석 이 키워드로 논문 검색

Stomach neoplasm, Combination Chemotherapy, Infusional 5-FU, Leucovorin, Docetaxel